Chemotherapy in Head and Neck Cancer Clinical Predictors of Tolerance and Outcomes

被引:12
|
作者
Kubicek, Gregory J. [1 ]
Kimler, Bruce F. [2 ]
Wang, Fen [2 ]
Reddy, Eashwer K. [2 ]
Girod, Douglas A. [3 ]
Williamson, Steven K. [4 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA USA
[2] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA
[4] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2011年 / 34卷 / 04期
关键词
head and neck cancer; chemotherapy; capsulation; tolerance; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; RANDOMIZED TRIAL; RADIOTHERAPY; CISPLATIN; CHEMORADIOTHERAPY; CARBOPLATIN; TIME;
D O I
10.1097/COC.0b013e3181e9c0a2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The addition of chemotherapy is more efficacious than radiation alone in the treatment of head and neck cancer (HNC). However, little data are available regarding the best chemotherapy agent and dosing, or factors associated with chemotherapy compliance. Methods: Retrospective review of all HNC patients receiving combined chemotherapy and radiotherapy at the University of Kansas Medical Center between 1994 and 2006. A total of 172 patients were analyzed in this report. Results: A total of 37% of patients were able to complete the entire chemotherapy regimen as intended. Multiple factors were examined in relation to chemotherapy completion and clinical outcome. Factors associated with not being able to complete chemotherapy on Cox regression analysis include use of a platinum agent and older age at diagnosis. No chemotherapy-related variables were prognostic for overall survival or disease-free survival. Conclusion: Factors associated with reduced chemotherapy compliance include older age and cisplatin agent. None of the chemotherapy characteristics (agent, total dose, and schedule) were associated with outcome.
引用
收藏
页码:380 / 384
页数:5
相关论文
共 50 条
  • [41] Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer
    Fabregas, Jesus C.
    Loaiza-Bonilla, Arturo
    Talebi, Toni N.
    Warsch, Sean
    Fernandez, Gustavo
    Raez, Luis E.
    Santos, Edgardo S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (09) : 1065 - 1072
  • [42] Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
    Bauman, Julie E.
    Cohen, Ezra
    Ferris, Robert L.
    Adelstein, David J.
    Brizel, David M.
    Ridge, John A.
    O'Sullivan, Brian
    Burtness, Barbara A.
    Butterfield, Lisa H.
    Carson, William E.
    Disis, Mary L.
    Fox, Bernard A.
    Gajewski, Thomas F.
    Gillison, Maura L.
    Hodge, James W.
    Quynh-Thu Le
    Raben, David
    Strome, Scott E.
    Lynn, Jean
    Malik, Shakun
    CANCER, 2017, 123 (07) : 1259 - 1271
  • [43] Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy
    Morse, Ryan T.
    Ganju, Rohit G.
    Neeranjun, Rishi
    Gan, Gregory N.
    Cao, Ying
    Neupane, Prakash
    Kakarala, Kiran
    Shnayder, Yelizaveta
    Lominska, Christopher E.
    CHEMOTHERAPY, 2023, 68 (01) : 35 - 43
  • [44] Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence
    Marcu, Loredana G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 103 : 27 - 36
  • [45] Burden of treatment: Reported outcomes in a head and neck cancer survivorship clinic
    Nilsen, Marci Lee
    Mady, Leila J.
    Hodges, Jacob
    Wasserman-Wincko, Tamara
    Johnson, Jonas T.
    LARYNGOSCOPE, 2019, 129 (12) : E437 - E444
  • [46] RADIATION THERAPY IN THE MANAGEMENT OF HEAD-AND-NECK CANCER OF UNKNOWN PRIMARY ORIGIN: HOW DOES THE ADDITION OF CONCURRENT CHEMOTHERAPY AFFECT THE THERAPEUTIC RATIO?
    Chen, Allen M.
    Farwell, D. Gregory
    Lau, Derick H.
    Li, Bao-Qing
    Luu, Quang
    Donald, Paul J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : 346 - 352
  • [47] Cetuximab, Paclitaxel, Carboplatin, and Radiation For Head and Neck Cancer A Toxicity Analysis
    Birnbaum, Ariel
    Dipetrillo, Thomas
    Rathore, Ritesh
    Anderson, Elliott
    Wanebo, Harry
    Puthwala, Yacoub
    Joyce, Donald
    Safran, Howard
    Henderson, Denise
    Kennedy, Theresa
    Ready, Neal
    Sio, Terence Tai-Weng
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 144 - 147
  • [48] Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience
    Mezi, Silvia
    Pomati, Giulia
    Botticelli, Andrea
    Roberto, Michela
    Cerbelli, Bruna
    Cirillo, Alessio
    Di Gioia, Cira
    Corsi, Alessandro
    Vullo, Francesco
    De Vincentiis, Marco
    Polimeni, Antonella
    Tombolini, Vincenzo
    Valentini, Valentino
    Marchetti, Paolo
    ANTI-CANCER DRUGS, 2020, 31 (10) : 1074 - 1083
  • [49] Outcomes and Management of Head and Neck Cancer at a South Indian Cancer Centre: A Retrospective Study
    Nagarajan, Murugaiyan
    Banu, Ramesh
    Shrividhya, Ananthakrishnan
    Chellapandian, Thirumalai Palanichamy
    Rajkumar, Arumugham
    Mohanraj, Ramaswamy
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2022, 43 (06) : 500 - 506
  • [50] Prognostic Factors in Patients Irradiated for Recurrent Head-and-Neck Cancer
    Seidl, Daniel
    Schild, Steven E.
    Wollenberg, Barbara
    Hakim, Samer G.
    Rades, Dirk
    ANTICANCER RESEARCH, 2016, 36 (12) : 6547 - 6550